{"id":742099,"date":"2011-08-26T07:08:00","date_gmt":"2011-08-26T07:08:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/texas-supreme-court-finds-for-merck-in-vioxx-case\/"},"modified":"2026-08-10T13:01:16","modified_gmt":"2026-08-10T17:01:16","slug":"texas-supreme-court-finds-for-merck-in-vioxx-case","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/texas-supreme-court-finds-for-merck-in-vioxx-case\/","title":{"rendered":"Texas Supreme Court Finds for Merck in VIOXX\u00ae Case"},"content":{"rendered":"<p>\n      Merck, known as MSD outside the United States and Canada, said today<br \/>\n      that the Texas Supreme Court overturned a judgment in favor of the<br \/>\n      family of Leonel Garza Sr. in a suit alleging that VIOXX caused Mr.<br \/>\n      Garza\u2019s death.\n    <\/p>\n<p>\n      The San Antonio Court of Appeals had previously overturned the verdict<br \/>\n      due to jury misconduct and ordered a new trial. The Texas Supreme Court<br \/>\n      found that the evidence did not support the plaintiffs therefore ordered<br \/>\n      final judgment in favor of Merck.\n    <\/p>\n<p>\n      In today\u2019s opinion, Justice Nathan L. Hecht wrote for the court: &#8220;we . .<br \/>\n      . hold that the Garzas did not present reliable evidence of general<br \/>\n      causation and are therefore not entitled to recover against Merck.&#8221;\n    <\/p>\n<p>\n      \u201cToday&#8217;s decision reaffirms that there is simply no reliable scientific<br \/>\n      evidence that VIOXX caused the plaintiff&#8217;s heart attack,\u201d said Ted Mayer<br \/>\n      of Hughes Hubbard &amp; Reed, outside counsel for Merck.\n    <\/p>\n<p>\n      The Texas Court of Appeals had reversed the jury&#8217;s verdict and ordered a<br \/>\n      retrial. The jury&#8217;s original verdict on April 21, 2006 included $7<br \/>\n      million in compensatory damages and $25 million in punitive damages. On<br \/>\n      Dec. 21, 2006, the punitive award was reduced to $750,000 in compliance<br \/>\n      with Texas statutory caps.\n    <\/p>\n<p>\n      During the trial, Merck was represented by Richard L. Josephson and<br \/>\n      Travis J. Sales of Baker Botts L.L.P., Houston, Texas. Merck&#8217;s lead<br \/>\n      appellate counsel is Baker Botts partner Stephen G. Tipps.\n    <\/p>\n<p>\n      On Nov. 9, 2007, Merck announced that it had entered into an agreement<br \/>\n      to resolve myocardial infarction and stroke claims filed as of that date<br \/>\n      in the United States. The $4.85 billion program established by the<br \/>\n      agreement resolved more than 99.9 percent of eligible claims in the<br \/>\n      United States. The Garza case was excluded from the program.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merck.com&amp;esheet=50276031&amp;lan=en-US&amp;anchor=www.merck.com.&amp;index=1&amp;md5=1aecada4e8042a99944f7389965a01d2\"><span class=\"bwuline\">www.merck.com<\/span>.<\/a>\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. Such statements may include,<br \/>\n      but are not limited to, statements about the benefits of the merger<br \/>\n      between Merck and Schering-Plough, including future financial and<br \/>\n      operating results, the combined company\u2019s plans, objectives,<br \/>\n      expectations and intentions and other statements that are not historical<br \/>\n      facts. Such statements are based upon the current beliefs and<br \/>\n      expectations of Merck\u2019s management and are subject to significant risks<br \/>\n      and uncertainties. Actual results may differ from those set forth in the<br \/>\n      forward-looking statements.\n    <\/p>\n<p>\n      The following factors, among others, could cause actual results to<br \/>\n      differ from those set forth in the forward-looking statements: the<br \/>\n      possibility that the expected synergies from the merger of Merck and<br \/>\n      Schering-Plough will not be realized, or will not be realized within the<br \/>\n      expected time period; the impact of pharmaceutical industry regulation<br \/>\n      and health care legislation; the risk that the businesses will not be<br \/>\n      integrated successfully; disruption from the merger making it more<br \/>\n      difficult to maintain business and operational relationships; Merck\u2019s<br \/>\n      ability to accurately predict future market conditions; dependence on<br \/>\n      the effectiveness of Merck\u2019s patents and other protections for<br \/>\n      innovative products; the risk of new and changing regulation and health<br \/>\n      policies in the U.S. and internationally and the exposure to litigation<br \/>\n      and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2010 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=50276031&amp;lan=en-US&amp;anchor=www.sec.gov%29.&amp;index=2&amp;md5=d2ecc756e3624dd7a36ed2f9ec42d6d4\"><span class=\"bwuline\">www.sec.gov<\/span>).<\/a>\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120514005672r1&amp;sid=sfsite1&amp;distro=nx\" \/><span class=\"bwct31415\" \/><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck, known as MSD outside the United States and Canada, said today that the Texas Supreme Court overturned a judgment in favor of the family of Leonel Garza Sr. in a suit alleging that VIOXX caused Mr. Garza\u2019s death. The San Antonio Court of Appeals had previously overturned the verdict due to jury misconduct and ordered a new trial. The Texas Supreme Court found that the evidence did not support the plaintiffs therefore ordered final judgment in favor of Merck. In today\u2019s opinion, Justice Nathan L. Hecht wrote for the court: &#8220;we . . . hold that the Garzas did not present reliable evidence of general causation and are therefore not entitled to recover against Merck.&#8221; \u201cToday&#8217;s decision reaffirms that there is simply no reliable scientific evidence that VIOXX caused the plaintiff&#8217;s heart attack,\u201d said Ted Mayer of Hughes Hubbard &amp; Reed, outside counsel for Merck. The Texas Court of Appeals had reversed the jury&#8217;s verdict and ordered a retrial. The jury&#8217;s original verdict on April 21,<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,289],"class_list":["post-742099","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Texas Supreme Court Finds for Merck in VIOXX\u00ae Case - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/texas-supreme-court-finds-for-merck-in-vioxx-case\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Texas Supreme Court Finds for Merck in VIOXX\u00ae Case - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck, known as MSD outside the United States and Canada, said today that the Texas Supreme Court overturned a judgment in favor of the family of Leonel Garza Sr. in a suit alleging that VIOXX caused Mr. Garza\u2019s death. The San Antonio Court of Appeals had previously overturned the verdict due to jury misconduct and ordered a new trial. The Texas Supreme Court found that the evidence did not support the plaintiffs therefore ordered final judgment in favor of Merck. In today\u2019s opinion, Justice Nathan L. Hecht wrote for the court: &quot;we . . . hold that the Garzas did not present reliable evidence of general causation and are therefore not entitled to recover against Merck.&quot; \u201cToday&#039;s decision reaffirms that there is simply no reliable scientific evidence that VIOXX caused the plaintiff&#039;s heart attack,\u201d said Ted Mayer of Hughes Hubbard &amp; Reed, outside counsel for Merck. The Texas Court of Appeals had reversed the jury&#039;s verdict and ordered a retrial. The jury&#039;s original verdict on April 21,\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/texas-supreme-court-finds-for-merck-in-vioxx-case\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-10T17:01:16+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20120514005672r1&sid=sfsite1&distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/texas-supreme-court-finds-for-merck-in-vioxx-case\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/texas-supreme-court-finds-for-merck-in-vioxx-case\\\/\",\"name\":\"Texas Supreme Court Finds for Merck in VIOXX\u00ae Case - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/texas-supreme-court-finds-for-merck-in-vioxx-case\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/texas-supreme-court-finds-for-merck-in-vioxx-case\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20120514005672r1&amp;sid=sfsite1&amp;distro=nx\",\"datePublished\":\"2011-08-26T07:08:00+00:00\",\"dateModified\":\"2026-08-10T17:01:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/texas-supreme-court-finds-for-merck-in-vioxx-case\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/texas-supreme-court-finds-for-merck-in-vioxx-case\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/texas-supreme-court-finds-for-merck-in-vioxx-case\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20120514005672r1&amp;sid=sfsite1&amp;distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20120514005672r1&amp;sid=sfsite1&amp;distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/texas-supreme-court-finds-for-merck-in-vioxx-case\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Texas Supreme Court Finds for Merck in VIOXX\u00ae Case\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Texas Supreme Court Finds for Merck in VIOXX\u00ae Case - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/texas-supreme-court-finds-for-merck-in-vioxx-case\/","og_locale":"en_US","og_type":"article","og_title":"Texas Supreme Court Finds for Merck in VIOXX\u00ae Case - Merck.com","og_description":"Merck, known as MSD outside the United States and Canada, said today that the Texas Supreme Court overturned a judgment in favor of the family of Leonel Garza Sr. in a suit alleging that VIOXX caused Mr. Garza\u2019s death. The San Antonio Court of Appeals had previously overturned the verdict due to jury misconduct and ordered a new trial. The Texas Supreme Court found that the evidence did not support the plaintiffs therefore ordered final judgment in favor of Merck. In today\u2019s opinion, Justice Nathan L. Hecht wrote for the court: \"we . . . hold that the Garzas did not present reliable evidence of general causation and are therefore not entitled to recover against Merck.\" \u201cToday's decision reaffirms that there is simply no reliable scientific evidence that VIOXX caused the plaintiff's heart attack,\u201d said Ted Mayer of Hughes Hubbard &amp; Reed, outside counsel for Merck. The Texas Court of Appeals had reversed the jury's verdict and ordered a retrial. The jury's original verdict on April 21,","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/texas-supreme-court-finds-for-merck-in-vioxx-case\/","og_site_name":"Merck.com","article_modified_time":"2026-08-10T17:01:16+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20120514005672r1&sid=sfsite1&distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/texas-supreme-court-finds-for-merck-in-vioxx-case\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/texas-supreme-court-finds-for-merck-in-vioxx-case\/","name":"Texas Supreme Court Finds for Merck in VIOXX\u00ae Case - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/texas-supreme-court-finds-for-merck-in-vioxx-case\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/texas-supreme-court-finds-for-merck-in-vioxx-case\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120514005672r1&amp;sid=sfsite1&amp;distro=nx","datePublished":"2011-08-26T07:08:00+00:00","dateModified":"2026-08-10T17:01:16+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/texas-supreme-court-finds-for-merck-in-vioxx-case\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/texas-supreme-court-finds-for-merck-in-vioxx-case\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/texas-supreme-court-finds-for-merck-in-vioxx-case\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120514005672r1&amp;sid=sfsite1&amp;distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120514005672r1&amp;sid=sfsite1&amp;distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/texas-supreme-court-finds-for-merck-in-vioxx-case\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Texas Supreme Court Finds for Merck in VIOXX\u00ae Case"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"7723eed6-1111-4efe-a072-24b9a75e7b4b","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742099","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742099\/revisions"}],"predecessor-version":[{"id":3679235,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742099\/revisions\/3679235"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742099"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742099"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}